Drugmakers Increase Prescription Med Prices in 2025

Prescription drug manufacturers raised prices on nearly 600 drugs in January, according to an analysis by 46brooklyn Research. Among those medications impacted by the increases are drugs used to treat diabetes, HIV, COVID-19, and cancer, as well as other conditions.

The Reuters news organization says most of the price increases are below 10%, with a median price increase of 4.5%. That number is in line with 2024, but lower than the 10% annual price hike that was standard for years.

Consumers can expect to pay more this year for Pfizer’s COVID-19 treatment, Paxlovid, as well as Novo Nordisk’s Type 2 diabetes drug, Ozempic, and cancer-related medications.

Wegovy, also made by Novo Nordisk with the same active ingredient as Ozempic, is not increasing its price . . . at least not yet.

It is expected that patients could pay more, but it depends on their health plans. NPR reports that if a drug is not covered by insurance, and its price increases, the out-of-pocket cost for consumers will likely increase. If it has been covered in the past, the insured could see a copay increase or higher coinsurance in 2025. Whether it’s part of the plan’s drug formulary is another consideration.

The impact of President Trump’s tariffs could also affect drug pricing in 2025. More than 90% of generic drugs in the U.S. are imported – most of which come from China and India.

 

Source Link

Recommended Articles

State PBM laws Face ERISA Preemption Challenges in Court

States seeking to limit the power of pharmacy benefit managers are running into legal roadblocks. Every state, as well as the federal government, has enacted PBM legislation over the last decade to rein in an industry accused of anticompetitive business practices. Those efforts have seen mixed results as agencies struggle to enforce requirements and courts ...

Read More

Employer Health Cost Crunch Is Worse Than Projected

There’s new evidence that double-digit health cost increases were hitting employers well before the forecasts of big spikes for 2027 — forcing big changes in workplace coverage for millions of Americans. Why it matters: The findings offer a higher-resolution view of how much health spending is putting a drag on the labor market and increasing ...

Read More

HHS Finalizes Changes To HIPAA Privacy Rule

HHS' Office for Civil Rights finalized a HIPAA privacy rule change cutting the protected health information request response window to 15 calendar days. The final regulation clarifies individuals can retrieve electronic PHI through health apps when entities can support that format.

Read More

Sutter Health-Allina Health Deal Clears Key Hurdle

Sutter Health and Allina Health have achieved a milestone in their plan to merge. The health systems agreed to invest $2.15 billion as part of a 10-year oversight arrangement that Minnesota Attorney General Keith Ellison (D) announced Monday. The deal has been under state review for months. Under terms of the agreement, Sacramento, California-based Sutter ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square